Johnson & Johnson reported positive topline Phase 3 MonumenTAL-6 results for Tecvayli plus Talvey in patients with relapsed or refractory multiple myeloma after one to four prior lines including anti-CD38 and lenalidomide exposure. Simultaneous…
Johnson & Johnson presented pivotal ENERGY Phase 2/3 data showing statistically significant durable hemoglobin responses for IMAAVY in warm autoimmune hemolytic anemia, supporting its February 2026 sBLA filing.
Johnson & Johnson announced more than 30 hematology presentations for EHA 2026, including key datasets from the Phase 3 MonumenTAL-3 and MajesTEC-9 multiple myeloma studies and pivotal Phase 2/3 ENERGY data for IMAAVY in…
